<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00009919</url>
  </required_header>
  <id_info>
    <org_study_id>NCI-2012-02373</org_study_id>
    <secondary_id>ID99-291</secondary_id>
    <secondary_id>N01CM17003</secondary_id>
    <secondary_id>CDR0000068424</secondary_id>
    <nct_id>NCT00009919</nct_id>
  </id_info>
  <brief_title>SU5416 in Treating Patients With Metastatic Kidney Cancer That Has Not Responded to Previous Treatment</brief_title>
  <official_title>Phase II Study of SU5416 (NSC 696819) for Patients With Progressive Metastatic Renal Cancer Failing Prior Biologic Therapy or 5-Fluorouracil Containing Regimens</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      Phase II trial to study the effectiveness of SU5416 in treating patients who have metastatic&#xD;
      kidney cancer that has not responded to previous therapy with interleukin-2. SU5416 may stop&#xD;
      the growth of kidney cancer by stopping blood flow to the tumor&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      I. Determine the clinical activity of SU5416 in patients with progressive metastatic renal&#xD;
      cancer failing prior biologic therapy or fluorouracil-containing regimens.&#xD;
&#xD;
      II. Determine the changes in tumor perfusion in patients treated with this regimen.&#xD;
&#xD;
      III. Determine the time to progression and survival in patients treated with this regimen.&#xD;
&#xD;
      OUTLINE:&#xD;
&#xD;
      Patients receive SU5416 IV over 1 hour twice weekly. Treatment continues every 6 weeks for at&#xD;
      least 2 courses in the absence of disease progression or unacceptable toxicity. Patients with&#xD;
      complete response (CR) receive an additional 6 months of therapy after achieving CR.&#xD;
&#xD;
      Patients are followed every 3 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Administratively complete.&#xD;
  </why_stopped>
  <start_date>December 2000</start_date>
  <primary_completion_date type="Actual">June 2003</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of progression-free events</measure>
    <time_frame>6 months</time_frame>
    <description>Estimated with associated confidence intervals using standard methods such as chi-square and Fisher's exact tests.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Objective response rate</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>Estimated with associated confidence intervals using standard methods such as chi-square and Fisher's exact tests.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Survival</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>Analyzed using Kaplan Meier curves and Cox proportional hazards models.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to disease progression</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>Analyzed using Kaplan Meier curves and Cox proportional hazards.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to treatment failure</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>Analyzed using Kaplan Meier curves and Cox proportional hazards.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>Analyzed using Kaplan Meier curves and Cox proportional hazards.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>Recurrent Renal Cell Cancer</condition>
  <condition>Stage IV Renal Cell Cancer</condition>
  <arm_group>
    <arm_group_label>Treatment (semaxanib)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive SU5416 IV over 1 hour twice weekly. Treatment continues every 6 weeks for at least 2 courses in the absence of disease progression or unacceptable toxicity. Patients with CR receive an additional 6 months of therapy after achieving CR.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>semaxanib</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (semaxanib)</arm_group_label>
    <other_name>semoxind</other_name>
    <other_name>SU5416</other_name>
    <other_name>Sugen 5416</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically confirmed metastatic renal cell carcinoma&#xD;
&#xD;
          -  Prior removal of primary tumors&#xD;
&#xD;
          -  Bidimensionally measurable disease&#xD;
&#xD;
               -  Bone-only disease is not considered measurable&#xD;
&#xD;
          -  Progressive disease following no more than 2 prior biologic therapy&#xD;
             (e.g.,interleukin-2, interferon alfa, vaccine, or dendritic cell therapy)&#xD;
             orfluorouracil-containing (single-agent or in combination therapy) regimens&#xD;
&#xD;
          -  No known history of CNS metastasis unless all of the following are true:&#xD;
&#xD;
               -  Previously treated&#xD;
&#xD;
               -  Neurologically stable&#xD;
&#xD;
               -  No requirement for IV steroids or anticonvulsants&#xD;
&#xD;
               -  No requirement for oral steroids and no evidence of active or residual CNS&#xD;
                  disease on CT scan or MRI&#xD;
&#xD;
          -  Negative brain scan (CT scan or MRI) required if neurologic signs or symptoms&#xD;
             suggestive of CNS metastasis present&#xD;
&#xD;
          -  Performance status - Zubrod 0-2&#xD;
&#xD;
          -  At least 12 weeks&#xD;
&#xD;
          -  Absolute neutrophil count at least 1,500/mm^3&#xD;
&#xD;
          -  Platelet count greater than 100,000/mm^3&#xD;
&#xD;
          -  Bilirubin no greater than 1.5 mg/dL&#xD;
&#xD;
          -  SGPT no greater than 2.5 times upper limit of normal&#xD;
&#xD;
          -  PT and PTT normal&#xD;
&#xD;
          -  Fibrinogen normal&#xD;
&#xD;
          -  D-Dimer assay normal&#xD;
&#xD;
          -  Creatinine no greater than 1.5 mg/dL&#xD;
&#xD;
          -  Creatinine clearance at least 60 mL/min&#xD;
&#xD;
          -  See Surgery&#xD;
&#xD;
          -  No active congestive heart failure&#xD;
&#xD;
          -  No uncontrolled angina&#xD;
&#xD;
          -  No myocardial infarction or severe/unstable angina within the past 6 months&#xD;
&#xD;
          -  No uncontrolled hypertension&#xD;
&#xD;
          -  No uncompensated coronary artery disease on electrocardiogram or physical examination&#xD;
&#xD;
          -  No severe peripheral vascular disease&#xD;
&#xD;
          -  No deep vein or arterial thrombosis within the past 3 months&#xD;
&#xD;
          -  No pulmonary embolism within the past 3 months&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  No concurrent serious infection&#xD;
&#xD;
          -  No overt psychosis, mental disability, or incompetence&#xD;
&#xD;
          -  No diabetes mellitus&#xD;
&#xD;
          -  No other prior malignancy within the past 5 years except curatively treated&#xD;
             nonmelanoma skin cancer or carcinoma in situ of the cervix&#xD;
&#xD;
          -  No hypersensitivity or allergic reaction to paclitaxel&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  No other concurrent anti-cancer biologic therapy&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  No concurrent anti-cancer chemotherapy&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  At least 4 weeks since prior radiotherapy and recovered&#xD;
&#xD;
          -  No sole indicator lesion within the previously irradiated port&#xD;
&#xD;
          -  No concurrent anti-cancer radiotherapy&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  At least 4 weeks since prior major surgery and recovered&#xD;
&#xD;
          -  At least 1 year since prior bypass surgery for atherosclerotic coronary artery disease&#xD;
&#xD;
          -  No concurrent surgery for cancer&#xD;
&#xD;
          -  No other investigational drugs (e.g., analgesics or antiemetics) for at least 28 days&#xD;
             prior to and after study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Arlene Siefker-Radtke</last_name>
    <role>Principal Investigator</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>M D Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2013</verification_date>
  <study_first_submitted>February 2, 2001</study_first_submitted>
  <study_first_submitted_qc>December 31, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 1, 2004</study_first_posted>
  <last_update_submitted>January 22, 2013</last_update_submitted>
  <last_update_submitted_qc>January 22, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 23, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Renal Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Semaxinib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

